| Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19: From the Emergency Cardiovascular Care Committee and Get With The Guidelines-Resuscitation Adult and Pediatric Task Forces of the American Heart Association | Circulation | 2020 | 216 |
| Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes | JAMA - Journal of the American Medical Association | 2020 | 155 |
| The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support | Circulation | 2020 | 148 |
| Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease | New England Journal of Medicine | 2020 | 138 |
| Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial | Circulation | 2020 | 130 |
| Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study | Lancet Diabetes and Endocrinology,the | 2020 | 109 |
| Effects of dapagliflozin in DAPA-HF according to background heart failure therapy | European Heart Journal | 2020 | 80 |
| Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus | Progress in Cardiovascular Diseases | 2020 | 73 |
| Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy | Circulation | 2020 | 69 |
| Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF | Circulation | 2020 | 68 |
| Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction | JACC: Heart Failure | 2020 | 65 |
| Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review | Journal of the American College of Cardiology | 2020 | 54 |
| Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF | Circulation | 2020 | 52 |
| Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial | JACC: Heart Failure | 2020 | 44 |
| Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) | European Heart Journal | 2020 | 40 |
| Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation | Lancet, The | 2020 | 39 |
| Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study | Lancet Diabetes and Endocrinology,the | 2020 | 37 |
| Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review | Journal of the American College of Cardiology | 2020 | 36 |
| Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction | European Journal of Heart Failure | 2020 | 35 |
| Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population | European Heart Journal | 2020 | 33 |
| Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease | New England Journal of Medicine | 2020 | 32 |
| Voluntary collective isolation as a best response to COVID-19 for indigenous populations? A case study and protocol from the Bolivian Amazon | Lancet, The | 2020 | 27 |
| Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis | Journal of Vascular Surgery: Venous and Lymphatic Disorders | 2020 | 27 |
| Code Blue During the COVID-19 Pandemic | Circulation: Cardiovascular Quality and Outcomes | 2020 | 27 |
| Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study | Diabetes Care | 2020 | 26 |
